|
Thrombolytic therapy needs
innovation
Barcelona, October 31, 2005:
Patent expiry of recombinant tissue-type plasminogen activator (t-PA) and
its TNK-derivative commencing in 2005 did not lead to biogeneric competition in
regulated markets. Combined net sales of Activase (t-PA) and TNKase in 2004 only
were US$ 200 mln, far away from a blockbuster status. Reasons are 1) competition
with low price veteran drugs streptokinase and urokinase which are purifed from
cell cultures; 2) competition with mechanical recanalization of occluded
coronary arteries in highly developed health care systems; 3) a narrow
therapeutic index due to the risk of intracerebral hemorrhage; and 4) a
time-limited therapeutic window in treatment of acute ischemic stroke. Ongoing
developments focus on plasminogen activators with higher fibrin selectivity in
combination with improved diagnostics and on innovative fibrinolytics directly
lysing the main target fibrin. These results were found in a search conducted by
La Merie Business Intelligence. The results were published in the October 31,
issue 15 of R&D Pipeline News, edited by La Merie.
Drug developers in non-regulated markets such as Cuba , Argentina , Korea ,
India and China predominantly preferred to manufacture recombinant
streptokinase, thus omitting old-fashioned purification of the protein from cell
culture preparations. The only generic development in regulated markets refers
to purified urokinase which is not yet approved and will face competition with
recombinant urokinase developed as a consequence of manufacturing problems with
the purified product. The recombinant product was investigated in occluded
central venous access devices (CVAD).
More recent developments of 5th generation thrombolytics differ from approved
thrombolytics and 4th generation plasminogen activators in advanced development
in their mechanism of action. The novel thrombolytics directly lyse fibrin which
- as a mesh - stabilizes the thrombus, without needing plasminogen the supply of
which may be limited in longer thrombi such as in peripheral artery occlusion.
Companies developing 5th generation thrombolytics avoid acute myocardial
infarction as an indication and focus on peripheral arterial diseae, acute
ischemic stroke and central venous catheter occlusion.
About La Merie
La Merie S.L. is a Business Intelligence enterprise fully dedicated to provide
high quality R&D information to the biopharmaceutical industry. La Merie offers
individual consultancy services and publishes reports and periodicals.
They publish two weekly
newsletters - apply for a FREE three week trial:
R&D Pipeline News is a premier
information source about research and development projects in the pipeline of
the biopharmaceutical industry and is directed to all stakeholders in R&D. The
weekly publication comes in a rapid- and easy-to-screen tabular format and
provides access to the original information source via hyperlinks. R&D Pipeline
News covers all relevant treatment modalities and is directly delivered to the
desktop via e-mail.
| 
